[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0308146A - Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto - Google Patents

Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Info

Publication number
BR0308146A
BR0308146A BR0308146-0A BR0308146A BR0308146A BR 0308146 A BR0308146 A BR 0308146A BR 0308146 A BR0308146 A BR 0308146A BR 0308146 A BR0308146 A BR 0308146A
Authority
BR
Brazil
Prior art keywords
compound
hydroxy
hydrogen
halo
alkyl
Prior art date
Application number
BR0308146-0A
Other languages
English (en)
Inventor
Alan Martin Birch
Andrew David Morley
Andrew Stocker
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0308146A publication Critical patent/BR0308146A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Amidas heterocíclicas de fórmula (1) em que: X é N ou CH; R^ 4^ e R^ 5^ em conjunto são -S-C(R^ 6^)=C(R^ 7^)- ou -C(R^ 7^)=C(R^ 6^)-S-; R^ 6^ e R^ 7^ são selecionados independentemente de, por exemplo hidrogênio, halo e alquila C~ 1-4~, A é fenileno ou heteroarileno; n é 0, 1 ou 2; R^ 1^ é selecionado, por exemplo, de halo, nitro, ciano, hidróxi, carbóxi; R^ 2^ é hidrogênio, hidróxi ou carbóxi; R^ 3^ é selecionado, por exemplo, de hidrogênio, hidróxi, arila, heterociclila e alquila C~ 1-4~ (opcionalmente substituido por 1 ou 2 grupos R^ 8^); R^ 8^ é selecionado, por exemplo, de hidróxi, -COCOOR^ 9^, -C(O)N(R^ 9^)(R^ 10^), -NHC(O)R^ 9^, (R^ 9^)(R^ 10^)N -COOR^ 9^; R^ 9^ e R^ 10^ são selecionados, por exemplo, de hidrogênio, hidróxi, alquila C~ 1-4~ (opcionalmente substituído por 1 ou 2 R^ 13^); R^ 13^ é selecionado de hidróxi, halo, trialometila e alcóxi C~ 1-4~; ou um seu sal ou pró-droga farmaceuticamente aceitável; apresentam atividade inibidora de glicogênio fosforilase e, assim, possuem são valiosas no tratamento de estados de doença associados com atividade incrementada de glicogênio fosforilase. Descreve-se processos para a manufatura de referidos derivados de amida heterocílica e composições farmacêuticas contendo os mesmos.
BR0308146-0A 2002-03-06 2003-03-04 Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto BR0308146A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205165.4A GB0205165D0 (en) 2002-03-06 2002-03-06 Chemical compounds
PCT/GB2003/000877 WO2003074532A1 (en) 2002-03-06 2003-03-04 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase

Publications (1)

Publication Number Publication Date
BR0308146A true BR0308146A (pt) 2004-12-07

Family

ID=9932329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308146-0A BR0308146A (pt) 2002-03-06 2003-03-04 Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Country Status (18)

Country Link
US (2) US7129249B2 (pt)
EP (1) EP1483270A1 (pt)
JP (1) JP2005526058A (pt)
KR (1) KR20040096661A (pt)
CN (1) CN100384852C (pt)
AR (1) AR038888A1 (pt)
AU (1) AU2003214377A1 (pt)
BR (1) BR0308146A (pt)
CA (1) CA2477667A1 (pt)
GB (1) GB0205165D0 (pt)
IL (1) IL163803A0 (pt)
MX (1) MXPA04008614A (pt)
NO (1) NO20043852L (pt)
NZ (1) NZ534990A (pt)
PL (1) PL372973A1 (pt)
TW (1) TW200305412A (pt)
WO (1) WO2003074532A1 (pt)
ZA (1) ZA200406679B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
BR0313825A (pt) * 2002-08-29 2005-07-12 Merck & Co Inc Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0320422D0 (en) * 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
EP1709004A2 (en) 2003-12-29 2006-10-11 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
ATE438645T1 (de) * 2004-01-31 2009-08-15 Sanofi Aventis Deutschland 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
DE102005063244A1 (de) * 2005-12-21 2007-06-28 Eberhard-Karls-Universität Tübingen Modifiziertes 2-Nitroimidazol-Derivat
ES2594156T3 (es) 2006-01-06 2016-12-16 Sunovion Pharmaceuticals Inc. Cicloalquilaminas como inhibidores de la recaptación de monoaminas
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US20090312559A1 (en) * 2006-01-10 2009-12-17 Hoveyda Amir H Catalytic enantioselective silylations of substrates
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008151156A1 (en) 2007-05-31 2008-12-11 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
SG10201406631TA (en) * 2009-10-16 2014-11-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EA201270568A1 (ru) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. Антимикробные композиции и способы их получения и применения
WO2016145417A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA3023317A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
CN109553580B (zh) * 2017-09-25 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物中间体及其盐的制备方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE200740C (pt)
US3706810A (en) 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4668769A (en) 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4720503A (en) 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH02124756A (ja) 1988-07-27 1990-05-14 Suzuki Sangyo Kk セメンティング組成物
JPH04179949A (ja) 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料
EP0644892A1 (en) 1992-06-12 1995-03-29 Pfizer Inc. Inhibitors of angiotensin i chymase(s) including human heart chymase
ES2081747B1 (es) 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
AU1890295A (en) 1994-03-09 1995-09-25 Novo Nordisk A/S Piperidines and pyrrolidines
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
DE4445968A1 (de) 1994-12-22 1996-06-27 Bayer Ag Verwendung von Sulfonylguanazinen
ATE205477T1 (de) 1995-06-06 2001-09-15 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
ES2164151T3 (es) 1995-06-06 2002-02-16 Pfizer N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa.
WO1996039384A1 (en) 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP1040827A3 (en) 1995-09-08 2000-10-11 Novo Nordisk A/S Use of 2-alkylpyrrolidines for the treatment of diabetes
WO1997031901A1 (en) 1996-02-29 1997-09-04 Mikael Bols Hydroxyhexahydropyridazines
EP0914322A1 (en) 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
ZA981920B (en) 1997-03-07 1998-09-07 Novo Nordisk As Novel heterocyclic compounds
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
EP1150674A1 (en) 1999-02-12 2001-11-07 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
US6043091A (en) 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
AU7404700A (en) 1999-09-29 2001-04-30 Novo Nordisk A/S Novel aromatic compounds
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
EP1233962B1 (fr) 1999-11-05 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composes heterocycliques et leur application a titre de medicaments
ES2436610T3 (es) 2000-01-21 2014-01-03 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
EP1145717B1 (en) 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002026714A1 (fr) 2000-09-27 2002-04-04 Takeda Chemical Industries, Ltd. Composes spiraniques
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1338594A4 (en) 2000-11-01 2004-06-16 Shionogi & Co PGD2 RECEPTOR ANTAGONIST PHARMACEUTICAL COMPOSITIONS
WO2002080844A2 (en) 2001-04-04 2002-10-17 Genzyme Corporation Novel bgp compounds for therapy and diagnosis and methods for using same
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
CA2465382A1 (en) 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
JP2005518365A (ja) 2001-11-27 2005-06-23 メルク エンド カムパニー インコーポレーテッド 4−アミノキノリン化合物
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
WO2003091213A1 (fr) 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
BR0316099A (pt) 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
BRPI0409465A (pt) 2003-04-17 2006-05-02 Pfizer Prod Inc derivados de carboxamida como agentes antidiabéticos
WO2004096768A1 (en) 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CA2477667A1 (en) 2003-09-12
WO2003074532A1 (en) 2003-09-12
JP2005526058A (ja) 2005-09-02
IL163803A0 (en) 2005-12-18
NZ534990A (en) 2006-02-24
KR20040096661A (ko) 2004-11-16
NO20043852L (no) 2004-09-14
ZA200406679B (en) 2005-01-18
US7129249B2 (en) 2006-10-31
AR038888A1 (es) 2005-02-02
CN1653070A (zh) 2005-08-10
MXPA04008614A (es) 2004-12-06
AU2003214377A1 (en) 2003-09-16
US7276517B2 (en) 2007-10-02
EP1483270A1 (en) 2004-12-08
CN100384852C (zh) 2008-04-30
TW200305412A (en) 2003-11-01
GB0205165D0 (en) 2002-04-17
US20050131015A1 (en) 2005-06-16
PL372973A1 (en) 2005-08-08
US20070043069A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR0308653A (pt) Cristais de derivado de benzeno de glicopiranosiloxibenzila
BRPI0413233A (pt) novos compostos
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
DE60017115D1 (de) Amid-derivate und deren medizinische verwendung
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
NO986055L (no) Nye heterocykliske forbindelser, deres fremstilling, farmas°ytiske preparater inneholdende forbindelsene og deres anvendelse ved behandling av diabetes og beslektede sykdommer
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
BR9916590A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica
BR0214989A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
WO2008002596A3 (en) Adenosine a2a receptor antagonists
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
ATE402696T1 (de) Heterozyklische amidderivate, die glycogen phosphorylase inhibierende aktivität besitzen
TW200716547A (en) Piperidin-4-yl-amide derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.